Eli Lilly and Company’s investigational drug, retatrutide, a groundbreaking triple hormone receptor agonist, has delivered an average weight loss of…
Read More

Eli Lilly and Company’s investigational drug, retatrutide, a groundbreaking triple hormone receptor agonist, has delivered an average weight loss of…
Read More
A groundbreaking preclinical study conducted by Northwestern Medicine researchers has unveiled a critical link between the decline of estrogen production…
Read More
A drug combination that has become a cornerstone of modern longevity research may carry unforeseen and devastating consequences for neurological…
Read More
Researchers from the Department of Medicine at the School of Clinical Medicine, LKS Faculty of Medicine, University of Hong Kong…
Read More
The global landscape of metabolic medicine has been fundamentally altered by the emergence of glucagon-like peptide-1 (GLP-1) receptor agonists. While…
Read More
The rapid rise of glucagon-like peptide-1 (GLP-1) receptor agonists has fundamentally altered the landscape of metabolic health and weight management…
Read More
The pharmaceutical landscape of the 21st century has been fundamentally altered by the rise of glucagon-like peptide-1 (GLP-1) receptor agonists.…
Read More
Findings presented at the 33rd European Congress on Obesity in Istanbul, Turkey, on May 15th, have provided a crucial comparative…
Read More
The political landscape of the United Kingdom has been significantly reshaped by the dramatic resignation of Wes Streeting, the UK…
Read More
On May 13, 2024, at the 33rd European Congress on Obesity (ECO) held in Istanbul, Türkiye, groundbreaking Phase 3b trial…
Read More